1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Accord Follows US Approval With EU Nod On Ustekinumab

Two Versions Of Stelara Biosimilar Approved As Absimky And Imuldosa

 
• By Dave Wallace

Accord has received a nod from the EMA for its Stelara biosimilar, while Neuraxpharm has seen a buprenorphine hybrid film endorsed and Viatris has received a positive CHMP opinion for an eltrombopag generic.

The CHMP endorsed several new products at its October meeting (Shutterstock)

The latest meeting of the European Medicines Agency’s Committee for Medicinal Products for Human Use has resulted in positive opinions for Accord Healthcare’s Stelara (ustekinumab) biosimilar as well as a buprenorphine hybrid film for Neuraxpharm and an eltrombopag generic for Viatris.

While CHMP positive opinions do not constitute formal approval, the European Commission typically acts within 67 days to convert them...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Kashiv’s Xolair Biosimilar Nears US And EU Filings As Phase III Data Reports

 
• By Urtė Fultinavičiūtė

Following the filing acceptance in the UK earlier this year, Kashiv and its three commercial musketeers – Alvotech, Advanz Pharma, and Amneal – are getting ready for applications in the US and Europe.

Formycon Signs US-Canada Deal With Valorum Biologics For Eylea Biosimilar

 
• By Urtė Fultinavičiūtė

Formycon continues to expand its partnership network with a fresh deal for its aflibercept biosimilar in the US and Canada. At the same time, the firm has received a high demand for its corporate bonds, leading to early offering closure.

Bio-Thera And SteinCares Add Mega-Blockbuster Dupilumab To Latin America Alliance

 
• By Dean Rudge

Bio-Thera Solutions is back with its third agreement with Costa Rica-based SteinCares for the supply of a biosimilar in Latin America – this time for the Chinese firm’s proposed rival to Sanofi and Regeneron’s Dupixent (dupilumab)

Biocon Agreement Provides Multiple Oncology Biosimilars To Malaysian Cancer NGO

 
• By Dean Rudge

Biocon Biologics will look to combine its “scientific expertise with the National Cancer Society of Malaysia’s strong community outreach and patient support network,” after signing striking up a partnership with the NGO providing for supply of three biosimilars.

More from Generics